ClinicalTrials.gg
CompletedNCT07433127Updated Aug 18, 2026

Inflammation Indıces and Mortality in Adult Crush Syndrome

An observational study in Crush Syndrome, Rhabdomyolysis and Systemic Inflammatory Response, sponsored by Ataturk University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Ataturk University · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
325
Ages
18 Years and older
Sex
All
01

Study summary

This single-center, retrospective observational cohort study evaluated the prognostic value of complete blood count-derived inflammatory indices - the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), systemic inflammatory response index (SIRI), and pan-immune-inflammation value (PIV) - for the prediction of 28-day mortality in adult patients with crush syndrome admitted to the intensive care unit (ICU).

Consecutive patients aged 18 years and older who were diagnosed with crush syndrome and admitted to the ICU between January 1, 2018, and September 30, 2025, were included. All indices were calculated from the complete blood count obtained within the first 24 hours of ICU admission. The primary and only outcome was 28-day mortality. The discrimination and independent prognostic value of the inflammatory indices were compared with the APACHE II and SOFA scores, and their incremental value beyond these established severity scores was assessed.

Read the detailed description

Crush syndrome is a life-threatening consequence of traumatic rhabdomyolysis, characterized by a systemic inflammatory response, acute kidney injury, electrolyte disturbances, and multi-organ dysfunction, with the highest mortality observed among patients requiring intensive care. Early and objective risk stratification is essential for guiding fluid resuscitation, informing the timing of renal replacement therapy, and allocating critical care resources.

In this single-center, retrospective cohort study, adult patients (≥18 years) diagnosed with crush syndrome and admitted to the intensive care unit of Ataturk University Research Hospital between January 1, 2018, and September 30, 2025, were identified from the hospital electronic health information system. The diagnosis was based on a compatible history of crush injury together with a serum creatine kinase level exceeding five times the upper limit of normal. Patients with conditions that directly alter hematological indices - hematological malignancy, active chemotherapy, chronic immunosuppressive therapy, massive transfusion within the first 24 hours, or known thrombocytopenia - were excluded. Demographic data, complete blood count parameters, and disease-severity scores were retrieved from electronic medical records.

The following inflammatory indices were calculated from the complete blood count obtained within the first 24 hours of ICU admission: NLR (neutrophils/lymphocytes), PLR (platelets/lymphocytes), MLR (monocytes/lymphocytes), SII (platelets × neutrophils/lymphocytes), SIRI (neutrophils × monocytes/lymphocytes), and PIV (neutrophils × platelets × monocytes/lymphocytes).

The primary and only endpoint was 28-day mortality following ICU admission. Group comparisons were performed using the Mann-Whitney U and Student t tests. Discrimination for 28-day mortality was assessed by receiver operating characteristic (ROC) curve analysis, and the areas under the curve were compared with the DeLong test. Because the six indices are deterministic ratios of four blood-count components and are therefore highly collinear, each index was entered into a separate logistic regression model together with the APACHE II and SOFA scores, rather than including all indices in a single model. The incremental discriminatory value of each index beyond an APACHE II plus SOFA base model was quantified as the change in the area under the curve, and internal validity was examined by bootstrapping. The study aimed to determine whether these readily available hematological indices provide prognostic value beyond established severity scores in critically ill patients with crush syndrome.

02

Conditions studied

  • Crush Syndrome
  • Rhabdomyolysis
  • Systemic Inflammatory Response
  • Critical Illness

Keywords

  • Neutrophil-to-Lymphocyte Ratio
  • NLR
  • Platelet-to-Lymphocyte Ratio
  • PLR
  • Monocyte-to-Lymphocyte Ratio
  • MLR
  • Systemic Immune-Inflammation Index
  • SII
  • Systemic Inflammatory Response Index
  • SIRI
  • Pan-Immune-Inflammation Value
  • PIV
  • APACHE II
  • SOFA SCORE
  • 28-day Mortality
  • Intensive Care Unit
03

In context

Rhabdomyolysis

40 studies on the registry are indexed under Rhabdomyolysis; 5 are open to participants now.

This study's enrollment of 325 is above the median of 150 across 23 observational studies indexed under Rhabdomyolysis.

Browse Rhabdomyolysis studies →

Lead sponsor

Ataturk University is the lead sponsor of 460 studies on the registry; 126 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients diagnosed with crush syndrome and admitted to the intensive care unit of Ataturk University Hospital between January 2018 and September 2025.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Diagnosis of crush syndrome based on clinical and laboratory findings
  • Admission to the intensive care unit (ICU) between January 1, 2018 and September 30, 2025
  • Availability of complete blood count parameters within the first 24 hours of ICU admission

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years
  • Incomplete medical records
  • Missing laboratory data required for calculation of inflammatory indices
  • Patients discharged or transferred within 24 hours of ICU admission
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
325 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. 28-day All-Cause Mortality

    All-cause mortality within 28 days of intensive care unit (ICU) admission in adult patients with crush syndrome.

    Time frame: 28 days from ICU admission

07

Study locations

1 site
  • Ataturk University Research Hospital
    Erzurum, 20100, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Oct 2025, 93 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2026
First posted
Feb 25, 2026
StartActual
Jan 1, 2018
Primary completionActual
Oct 28, 2025
CompletionActual
Oct 28, 2025
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07433127
Lead sponsor
Ataturk University
Responsible party
Nazim Dogan Prof. M.D (Professor of Anesthesiology and Reanimation, Ataturk University) — Principal investigator
First posted
Feb 25, 2026
Start date
Jan 1, 2018
Primary completion
Oct 28, 2025
Completion
Oct 28, 2025
Last update
Aug 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion